MAM
BPMC

Martingale Asset Management’s Blueprint Medicines BPMC Stock Holding History

Martingale Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,592
Closed -$1.87M – 763
2025
Q2 		$1.87M Sell
14,592
-901
-6% -$93.6K 0.05% 318
2025
Q1 		$1.37M Sell
15,493
-500
-3% -$48.8K 0.03% 388
2024
Q4 		$1.39M Buy
15,993
+390
+2% +$35.7K 0.03% 397
2024
Q3 		$1.44M Buy
15,603
+1,098
+8% +$109K 0.03% 392
2024
Q2 		$1.56M Buy
14,505
+490
+3% +$49K 0.03% 356
2024
Q1 		$1.33M Sell
14,015
-300
-2% -$25.7K 0.03% 395
2023
Q4 		$1.32M Sell
14,315
-1,798
-11% -$116K 0.03% 384
2023
Q3 		$809K Sell
16,113
-107
-0.7% -$5.72K 0.02% 498
2023
Q2 		$1.03M Sell
16,220
-402
-2% -$21.9K 0.02% 441
2023
Q1 		$748K Buy
+16,622
New +$749K 0.01% 521
2022
Q1 		– Sell
-16,225
Closed -$1.74M – 809
2021
Q4 		$1.74M Sell
16,225
-11,053
-41% -$1.16M 0.02% 345
2021
Q3 		$2.81M Buy
27,278
+12,860
+89% +$1.2M 0.04% 225
2021
Q2 		$1.27M Buy
14,418
+9,807
+213% +$899K 0.01% 345
2021
Q1 		$449K Buy
4,611
+1,104
+31% +$110K 0.01% 638
2020
Q4 		$394K Sell
3,507
-5,596
-61% -$590K ﹤0.01% 678
2020
Q3 		$844K Sell
9,103
-1,400
-13% -$108K 0.01% 680
2020
Q2 		$820K Buy
+10,503
New +$710K 0.01% 776

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Martingale Asset Management's BPMC Position: Q3 2025 in Review

Martingale Asset Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 14,592 shares — an estimated $1.87M sold.

Martingale Asset Management first reported a position in BPMC in Q2 2020 and held it in 17 quarters. The position peaked at $2.81M in Q3 2021. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Martingale Asset Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Martingale Asset Management sold 14,592 Blueprint Medicines shares in Q3 2025, an estimated $1.87M.
  • Martingale Asset Management first reported a position in Blueprint Medicines in Q2 2020 and held it in 17 quarters.
  • Martingale Asset Management's Blueprint Medicines position peaked at $2.81M in Q3 2021.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Martingale Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.